X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs DIVIS LABORATORIES - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD DIVIS LABORATORIES LUPIN LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 29.5 35.4 83.3% View Chart
P/BV x 2.8 6.9 41.0% View Chart
Dividend Yield % 0.6 0.7 90.3%  

Financials

 LUPIN LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
DIVIS LABORATORIES
Mar-18
LUPIN LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,4651,142 128.3%   
Low Rs727533 136.4%   
Sales per share (Unadj.) Rs349.6146.6 238.5%  
Earnings per share (Unadj.) Rs5.633.0 16.8%  
Cash flow per share (Unadj.) Rs29.638.4 77.0%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.51.2 38.2%  
Book value per share (Unadj.) Rs300.3222.8 134.8%  
Shares outstanding (eoy) m452.08265.47 170.3%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.15.7 54.9%   
Avg P/E ratio x197.225.3 778.0%  
P/CF ratio (eoy) x37.121.8 169.9%  
Price / Book Value ratio x3.63.8 97.1%  
Dividend payout %90.030.3 297.2%   
Avg Mkt Cap Rs m495,502222,318 222.9%   
No. of employees `00017.010.8 158.4%   
Total wages/salary Rs m28,6474,561 628.1%   
Avg. sales/employee Rs Th9,273.63,616.0 256.5%   
Avg. wages/employee Rs Th1,681.0423.8 396.7%   
Avg. net profit/employee Rs Th147.4814.9 18.1%   
INCOME DATA
Net Sales Rs m158,04238,915 406.1%  
Other income Rs m1,5041,134 132.5%   
Total revenues Rs m159,54540,049 398.4%   
Gross profit Rs m31,47512,617 249.5%  
Depreciation Rs m10,8591,425 762.1%   
Interest Rs m2,04413 15,364.7%   
Profit before tax Rs m20,07612,313 163.0%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,8853,543 81.4%   
Profit after tax Rs m2,5138,770 28.6%  
Gross profit margin %19.932.4 61.4%  
Effective tax rate %14.428.8 49.9%   
Net profit margin %1.622.5 7.1%  
BALANCE SHEET DATA
Current assets Rs m122,09545,351 269.2%   
Current liabilities Rs m50,9566,507 783.1%   
Net working cap to sales %45.099.8 45.1%  
Current ratio x2.47.0 34.4%  
Inventory Days Days85127 66.8%  
Debtors Days Days12095 126.0%  
Net fixed assets Rs m129,87621,160 613.8%   
Share capital Rs m904531 170.3%   
"Free" reserves Rs m134,86658,625 230.1%   
Net worth Rs m135,77159,156 229.5%   
Long term debt Rs m64,2450-   
Total assets Rs m263,05467,832 387.8%  
Interest coverage x10.8926.8 1.2%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.6 104.7%   
Return on assets %1.712.9 13.4%  
Return on equity %1.914.8 12.5%  
Return on capital %3.720.8 17.9%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m53,14132,359 164.2%   
Fx outflow Rs m19,3359,042 213.8%   
Net fx Rs m33,80723,317 145.0%   
CASH FLOW
From Operations Rs m17,5127,759 225.7%  
From Investments Rs m-14,073-4,783 294.2%  
From Financial Activity Rs m-14,921-3,142 474.9%  
Net Cashflow Rs m-11,482-166 6,916.7%  

Share Holding

Indian Promoters % 46.6 52.0 89.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 11.8 95.8%  
FIIs % 31.9 19.0 167.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.2 58.7%  
Shareholders   98,259 31,796 309.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Nov 20, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS